Jury awards Natera $83.7 million in damages

  • Jury rules in favor of Natera in patent infringement case against CareDX
  • Natera awarded $83.7 million in lost profits and $12.6 million in past royalties
  • CareDx products found to infringe Natera patents
  • All asserted claims of Natera patents deemed valid
  • Further proceedings to determine infringement of new versions of CareDx products

In a unanimous verdict, a jury in the U.S. District Court for the District of Delaware ruled in favor of Natera in its patent infringement case against CareDX. The jury awarded Natera $83.7 million in lost profits and $12.6 million in past royalties. The accused CareDx products, AlloSure and AlloSeq, were found to infringe one of the two Natera patents asserted against CareDx. Additionally, all asserted claims of both patents were deemed valid. Further proceedings will be scheduled to determine whether CareDx’s future sales of new versions of AlloSeq and AlloSure also infringe the asserted Natera patents. This victory comes after Natera successfully invalidated all three of CareDx’s patents in a separate lawsuit, with the invalidity of CareDx’s patents being affirmed on appeal.

Public Companies: Natera (NTRA), CareDx (CDNA)
Private Companies:
Key People:

Track all markets on TradingView

Factuality Level: 8
Justification: The article provides specific details about the patent infringement case between Natera and CareDx, including the amount awarded to Natera and the jury’s findings. It also mentions the previous lawsuit between the two companies and the invalidation of CareDx’s patents. However, the article lacks additional context or analysis, and it does not provide any opposing viewpoints or potential implications of the verdict.

Noise Level: 8
Justification: The article provides a brief summary of a patent infringement case between Natera and CareDx. However, it lacks in-depth analysis, scientific rigor, and intellectual honesty. It does not provide any evidence, data, or examples to support its claims. Additionally, it does not explore the consequences of the verdict on the parties involved or the broader implications for the industry. The article also dives into unrelated information about previous lawsuits, which is not relevant to the current case. Overall, the article contains mostly filler content and does not provide actionable insights or new knowledge.

Financial Relevance: Yes
Financial Markets Impacted: The financial markets impacted by this news article are the biotechnology and healthcare sectors. Natera’s victory in the patent infringement case against CareDx could have implications for the companies involved and their competitors in the industry.

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: This news article pertains to a legal verdict in a patent infringement case, which is relevant to the financial markets. However, there is no mention of an extreme event in the article.

Reported publicly: www.marketwatch.com